No, Mirtazapine is NOT an Antipsychotic
Mirtazapine is an antidepressant medication, specifically classified as a noradrenergic and specific serotonergic antidepressant (NaSSA), not an antipsychotic. According to FDA labeling, its mechanism of action involves antagonism at central presynaptic α2-adrenergic receptors and serotonin 5-HT2 and 5-HT3 receptors, enhancing noradrenergic and serotonergic activity for the treatment of major depressive disorder 1.
Primary Classification and Approved Use
Mirtazapine is FDA-approved exclusively for major depressive disorder 1. Multiple clinical guidelines consistently classify it as a sedating antidepressant, not an antipsychotic:
- Insomnia guidelines list mirtazapine among sedating antidepressants (alongside trazodone, doxepin, amitriptyline) as third-line options after benzodiazepine receptor agonists fail 2
- Depression treatment guidelines categorize it as a second-generation antidepressant with faster onset of action compared to SSRIs 3
- Palliative care guidelines describe it as an "atypical antidepressant" useful for depression, insomnia, and appetite stimulation—distinct from antipsychotics like quetiapine and olanzapine 4, 5
Why the Confusion May Arise
The confusion likely stems from three factors:
Sedating properties: Mirtazapine's antagonism of histamine H1 receptors produces prominent sedation 1, leading to its off-label use for insomnia 2
Mentioned alongside antipsychotics: Guidelines sometimes list mirtazapine in the same treatment algorithms as antipsychotics when discussing refractory insomnia, but they are clearly distinguished as separate drug classes 5
Emerging adjunctive research: Recent studies have explored adding mirtazapine to antipsychotics for schizophrenia, showing some benefit for negative symptoms 6, 7, 8. However, this represents augmentation of antipsychotic therapy, not mirtazapine functioning as an antipsychotic itself
Clinical Distinction from True Antipsychotics
True antipsychotics (like quetiapine, olanzapine, chlorpromazine) are explicitly listed as separate medication classes in clinical guidelines 2, 5. When guidelines discuss treatment sequences:
- Antipsychotics are reserved for specific indications: psychosis, severe agitation, or as last-line options for refractory insomnia
- Mirtazapine appears earlier in treatment algorithms as a sedating antidepressant option
- The two classes have fundamentally different mechanisms and indications
Important Caveats
While mirtazapine is definitively not an antipsychotic, clinicians should note:
- Off-label uses: Mirtazapine is used off-label for insomnia, anxiety, and appetite stimulation 4, 9, 5
- Side effect profile: Weight gain and sedation are common 2, 9, 1
- Drug interactions: Mirtazapine can interact with medications that prolong QTc interval, including some antipsychotics 1
- Dosing considerations: Lower doses (7.5-30 mg) are typically used for insomnia versus full antidepressant doses 9, 2
The bottom line: Mirtazapine is an antidepressant with sedating properties, not an antipsychotic. Its classification, FDA approval, mechanism of action, and clinical guideline positioning all confirm this distinction.